EXASEXACT SCIENCES CORP

Nasdaq exactsciences.com


$ 65.55 $ -1.85 (-2.75 %)    

Friday, 13-Sep-2024 15:59:58 EDT
QQQ $ 474.86 $ 2.12 (0.45 %)
DIA $ 414.87 $ 2.97 (0.72 %)
SPY $ 561.82 $ 2.92 (0.52 %)
TLT $ 100.40 $ 0.27 (0.27 %)
GLD $ 238.66 $ 2.35 (0.99 %)
$ 65.54
$ 64.62 x 100
-- x --
-- - --
$ 40.62 - $ 79.62
4,935,689
na
12.11B
$ 1.20
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

These ten stocks saw significant gains last week, with Summit Therapeutics up 98.32% and BioNTech up 31.77%. Analysts also rais...

 canaccord-genuity-maintains-buy-on-exact-sciences-maintains-75-price-target

Canaccord Genuity analyst Kyle Mikson maintains Exact Sciences (NASDAQ:EXAS) with a Buy and maintains $75 price target.

 piper-sandler-maintains-overweight-on-exact-sciences-raises-price-target-to-85

Piper Sandler analyst David Westenberg maintains Exact Sciences (NASDAQ:EXAS) with a Overweight and raises the price target ...

 exact-expects-fda-approval-for-cologuard-plus-in-second-half-of-2024-featuring-30-lower-false-positive-rate-compared-to-original-cologuard-improving-cancer-sensitivity-and-specificity

- Baird Global Healthcare Conference   

 exact-sciences-raises-their-2024-adjusted-ebitda-guidance-after-strong-q2-performance-achieving-record-profitability-expanding-margins-while-reinvesting-in-growth-aiming-for-over-20-ebitda-margins-by-2027

- Conference 

 watching-exact-sciences-shares-spike-higher-co-now-presenting-at-the-baird-global-healthcare-conference-in-a-fireside-chat-at-1015-am-et

Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company m...

 wells-fargo-initiates-coverage-on-exact-sciences-with-overweight-rating-announces-price-target-of-75

Wells Fargo analyst Brandon Couillard initiates coverage on Exact Sciences (NASDAQ:EXAS) with a Overweight rating and announ...

 exact-sciences-launches-multi-cancer-early-detection-study-with-25k-patients-supported-by-fda-authorization

Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the first...

 doordash-and-exact-sciences-are-among-top-10-large-cap-gainers-last-week-july-28-aug-3-are-the-others-in-your-portfolio

Top 10 stocks with highest gains last week, including Exact Sciences, Alnylam Pharmaceuticals, Resmed, Coca-Cola Consolidated, ...

 benchmark-maintains-buy-on-exact-sciences-lowers-price-target-to-67

Benchmark analyst Bruce Jackson maintains Exact Sciences (NASDAQ:EXAS) with a Buy and lowers the price target from $91 to $67.

 stifel-maintains-buy-on-exact-sciences-lowers-price-target-to-82

Stifel analyst Daniel Arias maintains Exact Sciences (NASDAQ:EXAS) with a Buy and lowers the price target from $100 to $82.

 exact-sciences-stock-climbs-after-strong-q2-results

Exact Sciences shares are trading higher after the company reported its second-quarter financial results Wednesday. Here's ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION